Novartis Ag (NVSEF) Net Income towards Common Stockholders (2009 - 2026)

Novartis Ag (NVSEF) has 16 years of Net Income towards Common Stockholders data on file, last reported at $1.65 in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 9.84% year-over-year to $1.65 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.02 (up 9.18% YoY) and the FY2025 annual result came in at $7.21, up 21.79% from the prior year.
• Net Income towards Common Stockholders climbed to $1.65 in Q1 2026 per NVSEF's latest filing, from $1.26 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $4.14 in Q4 2023, with the low at $0.69 in Q4 2022.
• Average Net Income towards Common Stockholders over 5 years is $1.48, with a median of $1.31 recorded in 2024.
• Year-over-year, Net Income towards Common Stockholders sank 90.53% in 2022 and jumped 500.0% in 2023.
• Novartis Ag's Net Income towards Common Stockholders stood at $0.69 in 2022, then jumped by 500.0% to $4.14 in 2023, then sank by 65.7% to $1.42 in 2024, then decreased by 11.27% to $1.26 in 2025, then surged by 30.95% to $1.65 in 2026.
• Business Quant data shows NVSEF's Net Income towards Common Stockholders at $1.65 in Q1 2026, $1.26 in Q4 2025, and $2.04 in Q3 2025.